QualityStocks would like to highlight Amarantus BioSciences, Inc. (OTCBB: AMBS), a development-stage biotechnology company focused on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson’s disease, traumatic brain injury (TBI), and other human diseases in the U.S. The company owns the intellectual property rights to a therapeutic protein, known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), which corrects protein misfolding.
In the company’s news yesterday,
Amarantus BioSciences announced it has received a Translational Research Grant award from the University of Massachusetts’ Pioneer Valley Life Sciences Institute’s Center of Excellence in Apoptosis Research (CEAR). The institute is a joint research venture between Baystate Medical Center and the University of Massachusetts Amherst.
Amarantus is a biotechnology company engaged in the development of new treatments for brain-related disorders, including Parkinson’s disease and traumatic brain injuries (TBI), and the company is centered on its unique proprietary anti-apoptotic therapeutic protein known as MANF. Investigators for the joint study with UMass Amherst will utilize publicly available genomics databases to identify new potential therapeutic targets for MANF-based therapeutics; they will then validate those hypotheses in cell-based laboratory research. The program could potentially lead to the identification and patenting of therapeutic indications for MANF that are beyond what has already been reported.
Literature relating to MANF has increased greatly in recent years, and there seems to be a solid rationale for investigating its potential uses in areas other than Parkinson’s disease. The study will complement work being done by other labs around the world that are focusing on MANF. The University of Massachusetts’ relationship with Amarantus will be critical in ensuring that the basic science behind MANF can be translated into clinical research in various other therapeutic indications.
The UMass grant will enable Amarantus to explore the full spectrum of the MANF opportunity. As Amarantus’ development program for Parkinson’s continues toward identifying MANF’s best delivery targets, the identification of additional disease targets for MANF therapy could greatly increase the value of the company’s intellectual property portfolio and, by extension, make Amarantus more attractive to potential partners.
Amarantus BioSciences is a development-stage biotechnology company. Founded in 2008, the company is focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns for treating and diagnosing Parkinson’s disease, traumatic brain injury, and other diseases. Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). The company is currently developing MANF-based products to be used as treatments for brain disorders and is also a founding member of the Coalition for Concussion Treatment. This movement, initiated in collaboration with Brewer Sports International, seeks to raise awareness of new treatments that are in development for concussions and nervous-system disorders.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.